Investment
Features
FeesSafety
Academy
More
Pluang+

Maple Gold Mines to join European investor roadshow showcasing its Quebec gold project.

Market News
18 Sep 2026
Newsfile Corp
View Source
Neutral
Maple Gold Mines to join European investor roadshow showcasing its Quebec gold project.

Maple Gold Mines Ltd. announced its participation in the Gentile Mining Investor Forum in London on October 19, followed by a European roadshow through Paris, Frankfurt, Zurich, and Munich from October 20-23, 2026. The events provide Maple Gold with opportunities to meet investors and present updates on its Douay/Joutel gold project in Quebec's Abitibi gold belt, which holds significant gold resources and exploration potential. This engagement aims to attract global investment to support the company's exploration and resource expansion efforts.

Maple Gold Mines Ltd.'s participation in the Gentile Mining Investor Forum and European roadshow is noted alongside Pluang's Basic Materials sector market data. For readers following Basic Materials stocks, here is Pluang's market snapshot as of Sep 18, 2026 19:13 WIB: out of 34 priced US stocks, 20 rose and 13 fell. Notable movers include Aspen Aerogels Inc (ASPN) with a price of USD 5.20 and 100% buy order activity, Teck Resources (TECK) at USD 66.08 with a 1.32% increase, and ArcelorMittal SA (MT) at USD 74.26 with a 1.22% decrease and 100% buy order activity.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
28 minutes ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
1 hour ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
1 hour ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
2 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App